Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression- Clinical and Mechanistic Impact.

Trial Profile

Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression- Clinical and Mechanistic Impact.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Sirolimus (Primary) ; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2017 Status changed from completed to discontinued.
    • 26 Oct 2016 Status changed from recruiting to completed.
    • 29 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top